Imunon Inc

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IMUNON reports Q1 loss, highlights promising cancer treatment progress

IMUNON shows progress in clinical trials with promising data; strong leadership and innovative technology driving growth. Financial challenges exist, but opportunities in expanding therapeutic applications and COVID vaccine development are promising.

Imunon Inc reports Q2 losses, optimistic on clinical advancements

Imunon Inc faces financial challenges but shows promise in clinical outcomes.
Strategic expense management and positive study results are key strengths.
Opportunities lie in partnerships, financing, and upcoming data releases.
Leadership's optimism reflects confidence in the company's progress.

Imunon Inc reports positive clinical results and secures funding for growth

Imunon Inc's Q3 2024 performance reflects promising clinical advancements and financial stability, with plans for a Phase III trial in the pipeline.
The company's strengths lie in strong clinical data, secured funding, strategic partnerships, and a focus on innovation in cancer therapies.
Challenges include managing increased expenses, navigating partnerships, competition, and regulatory hurdles, requiring careful strategic planning.
Opportunities abound in advancing to Phase III trials, exploring partnerships for the COVID-19 vaccine, and leveraging strategic hires for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

LAWRENCEVILLE, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today announced that on April 10, 2024, it received written notice from the staff of The NASDAQ Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market. Accordingly, IMUNON complies with all applicable listing standards, and its common stock will maintain its listing on the Nasdaq Capital Market under the symbol “IMNN.”

IMUNON Reports Compliance with Nasdaq Listing Requirements

Imunon, Inc. (IMNN) Q4 2023 Earnings Call Transcript

Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J.

IMUNON Reports 2023 Financial Results and Provides Business Update

Non-dilutive funding strengthens balance sheet and extends current operating runway LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, announces receipt of $1.3 million in net cash proceeds from the sale of approximately $1.4 million of its unused New Jersey net operating losses (NOLs).

IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses

LAWRENCEVILLE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 10:00 a.m. ET on Thursday, March 28, 2024 to discuss financial results for the year ended December 31, 2023 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines.

IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024

Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2 The application follows guidance provided to IMUNON in Pre-IND meeting with the FDA

IMUNON Files IND Application to Begin Human Testing of IMNN-101

Executive Chairman to lead day-to-day operations, active search underway for CEO successor.Timing of upcoming milestones for key programs remains unchanged.

IMUNON Announces Leadership Change

Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality

Independent Lab Confirms Immunogenicity and Protection with IMUNON's IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5

Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON's IMNN-001 in combination with bevacizumab in patients with advanced ovarian cancer.

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON's IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Data Show Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an article titled “Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer” by Subeena Sood, Majed M.

IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine

Accomplished pharmaceutical and biotechnology executive to lead IMUNON's clinical programs in ovarian cancer and infectious diseases

IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Imunon, Inc. (NASDAQ:IMNN ) Q3 2023 Earnings Call Transcript November 14, 2023 10:00 AM ET Company Participants Kim Golodetz - Investor Relations, LHA Corinne Le Goff - President & Chief Executive Officer Jeffrey Church - Chief Financial Officer Khursheed Anwer - Chief Science Officer Conference Call Participants Emily Bodnar - HC Wainwright James Molloy - Alliance Global Partners Kemp Dolliver - Brooklyn Capital Markets David Bautz - Zacks Small-Cap Research Operator Good morning. My name is Alan, and I will be your operator today.

Imunon, Inc. (IMNN) Q3 2023 Earnings Call Transcript

Dr. Jean Boyer to highlight updated data showing the advantages of IMUNON's PlaCCine modality and its applicability to multiple pathogens

IMUNON's VP of R&D to Present at the Vaccines Summit-2023

Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones

IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update

LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 10:00 a.m. ET on Tuesday, November 14, 2023 to discuss financial results for the third quarter and nine-months ended September 30, 2023 and provide an update on its clinical development of IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of advanced-stage ovarian cancer, and its preclinical studies of PLACCINE, a proprietary, multivalent DNA-based plasmid technology utilizing synthetic, non-viral delivery vectors, being evaluated in proof-of-concept studies for superiority over current mRNA vaccines.

IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023

Highlights advantages of IMUNON's PlaCCine modality over current commercial vaccines LAWRENCEVILLE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company focused on harnessing the power of the immune system against cancer and infectious diseases, announces that Khursheed Anwer, Ph.D.

IMUNON's Chief Science Officer to Present at the 3rd International Vaccines Congress

“ A Tale of Two Pandemics: Lessons From the 1889 & 2019 Pandemics” presented by the Foreign Policy Association

IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations

The MRD trial will evaluate the effect of this treatment combination on minimal residual disease. LAWRENCEVILLE, N.J.

IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer

Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON's FixPlas™ and Indiplas™ modalities in immuno-oncology.

IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board

Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001 + PARPi shows meaningful PFS and OS trend compared with control arm Continued follow-up is indicated to confirm initial observations LAWRENCEVILLE, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapies and next-generation vaccines, announces interim progression-free survival (PFS) and overall survival (OS) data with IMNN-001 in its Phase 1/2 OVATION 2 Study.

IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer

Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of IMUNON's newly relaunched website LAWRENCEVILLE, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced the release of an enterprise video that highlights the company's mission, vision, values, breakthroughs and technologies.

IMUNON Releases Enterprise Video Highlighting the Company's Mission, Vision, Values, Breakthroughs and Technologies

Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN) , a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, reminds investors of its virtual R&D Day event tomorrow, September 14th beginning at 4:00 p.m.

IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET

Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development

IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET

LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the IMUNON presentation will be available on the Events section of the Company's website beginning Monday, September 11 at 7:00 a.m. Eastern time.

IMUNON to Participate in the H.C. Wainwright Global Investment Conference

CRADA will evaluate the immunogenicity and efficacy of two DNA-based Lassa virus vaccine candidate s in animal models

News for Imunon Inc Stock (IMNN)